Exicure, Inc. (NASDAQ:XCUR - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 31st, there was short interest totalling 34,300 shares, a decline of 23.3% from the March 15th total of 44,700 shares. Based on an average daily volume of 62,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.4% of the shares of the stock are sold short.
Institutional Trading of Exicure
An institutional investor recently bought a new position in Exicure stock. Geode Capital Management LLC purchased a new position in shares of Exicure, Inc. (NASDAQ:XCUR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 12,645 shares of the company's stock, valued at approximately $173,000. Geode Capital Management LLC owned 0.48% of Exicure at the end of the most recent quarter. Institutional investors and hedge funds own 42.82% of the company's stock.
Exicure Stock Performance
Shares of XCUR traded up $0.84 during trading hours on Wednesday, hitting $12.20. 9,019 shares of the stock were exchanged, compared to its average volume of 569,263. Exicure has a 12-month low of $1.44 and a 12-month high of $36.00. The company has a market cap of $77.08 million, a price-to-earnings ratio of -5.89 and a beta of 3.74. The stock's 50-day moving average price is $11.33 and its two-hundred day moving average price is $11.09.
Exicure (NASDAQ:XCUR - Get Free Report) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($3.39) EPS for the quarter.
Exicure Company Profile
(
Get Free Report)
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
See Also
Before you consider Exicure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exicure wasn't on the list.
While Exicure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
